Can Shingles Cause Meningitis?

Shingles can cause meningitis, and it does so more often than most people realize. The varicella-zoster virus (VZV), the same virus behind chickenpox and shingles, is responsible for roughly 8 to 10 percent of aseptic meningitis cases, placing it among the more common viral culprits. What makes VZV meningitis especially tricky is that it sometimes shows up without any visible rash at all, which means doctors and patients alike can miss the connection to shingles entirely.

How Shingles Reaches the Brain’s Lining

After you recover from chickenpox, VZV doesn’t leave your body. It retreats into nerve clusters along the spine and skull, where it can remain dormant for decades. When the immune system weakens due to aging, stress, illness, or immunosuppressive medication, the virus can reactivate and travel along nerve fibers. Most of the time this produces the painful, blistering rash known as shingles. But the virus can also spread beyond the skin and into the central nervous system. When it inflames the membranes surrounding the brain and spinal cord, the result is meningitis.

VZV reactivation produces a surprisingly wide range of neurological problems beyond meningitis, including cranial nerve palsies, inflammation of the spinal cord, and a condition called VZV vasculopathy that damages blood vessels in the brain.¹ Meningitis is one of the more common of these complications, but all of them stem from the same underlying problem: the virus escaping the nerve ganglia and reaching structures it can damage.

Meningitis Without the Rash

One of the most disorienting aspects of VZV meningitis is that it can appear with no rash whatsoever. This condition, known as zoster sine herpete, means the virus reactivates and invades the central nervous system without producing the telltale blisters on the skin. Case reports describe otherwise healthy, immunocompetent young men developing full-blown VZV meningitis confirmed by spinal fluid testing, yet having no skin eruptions at any point during the illness.² The same phenomenon has been documented in children: a 12-year-old boy with a normal immune system developed meningitis from the vaccine strain of VZV, confirmed by detecting vaccine-type viral DNA in his spinal fluid, without ever developing a rash.³

This matters practically because when there is no rash, neither you nor your doctor has an obvious reason to suspect VZV. Meningitis symptoms like headache, fever, and neck stiffness get attributed to other causes, and the correct antiviral treatment can be delayed. Even when a rash does eventually appear, research shows it sometimes shows up days after the meningitis symptoms begin, not before. In one study, the rash followed meningitis symptoms by a median of six days in patients ultimately diagnosed with VZV.⁴ So even in cases where shingles is present, it can lag behind the neurological symptoms, creating a window of diagnostic confusion.

What VZV Meningitis Feels Like

The classic presentation is a severe headache, fever, and a stiff neck. These are the standard meningitis red flags regardless of the cause. But VZV meningitis doesn’t always follow the textbook. One documented case involved an immunocompetent adult whose main complaints were dizziness, loss of balance, diarrhea, and abdominal pain, mimicking a stroke rather than an infection of the brain’s lining.⁵ That patient had none of the headache, fever, or neck stiffness typically associated with the diagnosis.

Another case was initially mistaken for atopic dermatitis because the patient’s rash was painless and appeared on the back of the head rather than in a typical shingles distribution.⁶ The range of presentations means that VZV meningitis is probably underdiagnosed, especially in younger patients who aren’t expected to develop shingles complications and in anyone whose symptoms don’t line up neatly with the usual picture.

Who Is at Risk

The elderly and immunocompromised are at highest risk. As cell-mediated immunity against VZV naturally declines with age, the odds of reactivation climb, and so do the chances the virus will cause complications beyond a simple rash.¹ People on chemotherapy, organ transplant recipients taking anti-rejection drugs, and those living with HIV face particularly elevated risk.

But the case reports make clear that healthy, young, immunocompetent people get VZV meningitis too. Multiple published cases involve patients in their twenties and thirties with no known immune deficiency.² Ramsay Hunt syndrome, where VZV reactivation damages the facial nerve causing hearing loss and facial paralysis, has also been documented alongside meningitis in young adults with normal immune function.⁷ The takeaway is that while a weakened immune system increases risk substantially, a strong immune system is not a guarantee of protection.

How Doctors Confirm the Diagnosis

The gold standard for diagnosing VZV meningitis is a lumbar puncture, commonly called a spinal tap. Doctors analyze the cerebrospinal fluid for signs of infection and then run a PCR test to detect VZV DNA. When the virus is actively causing meningitis, the spinal fluid typically shows elevated protein levels, increased white blood cells (predominantly a type called lymphocytes), and a positive VZV PCR result.⁸

There is an important wrinkle, though. VZV DNA can show up in the spinal fluid during a regular shingles episode even when the virus isn’t actually causing brain or spinal cord disease.⁹ In other words, a positive PCR alone doesn’t automatically mean the patient has meningitis. Clinicians need to look at the full picture: are there enough white blood cells in the fluid to indicate inflammation? Does the protein level support an active infection? Are the symptoms consistent? When the PCR is positive but other markers are normal, the virus may just be shedding into the spinal fluid without truly invading the central nervous system.

In some cases, particularly when symptoms have been present for a while, PCR testing can come back negative even though VZV is the cause. When doctors suspect VZV meningitis but the PCR is unhelpful, testing for VZV-specific antibodies produced inside the spinal compartment can fill the gap. Calculating an antibody index can identify patients with central nervous system VZV infection who would otherwise be missed.¹⁰

Treatment and Why Timing Matters

The standard treatment for VZV meningitis is intravenous acyclovir, the same antiviral drug used for severe shingles. For patients well enough to be treated outside the hospital, oral valacyclovir is sometimes used instead, because it reaches much higher blood levels than oral acyclovir. Oral acyclovir on its own is a poor choice for central nervous system VZV infections: it has low bioavailability and limited penetration into the spinal fluid. Valacyclovir performs better on both counts, though doses need to be higher than those used for skin-only shingles.¹¹

Speed of treatment appears to be one of the strongest predictors of how well patients recover. A Japanese study found that each additional day of delay before starting intravenous acyclovir increased the odds of lingering symptoms by about 30 percent.¹² That finding underscores why the diagnostic challenges discussed earlier are not just academic concerns. When the rash is absent or atypical and doctors don’t suspect VZV, treatment is delayed, and outcomes suffer.

Recovery and Residual Symptoms

Most people survive VZV meningitis, and the majority recover well. Nationwide data from Japan tracking nearly 2,000 hospitalized patients found an in-hospital mortality rate below 1 percent. At discharge, the vast majority of patients were alert and functionally independent. The median hospital stay was about two weeks, with most patients going home within three.¹³

But “survived with a good outcome” isn’t the whole story. The same Japanese study that highlighted the importance of early treatment found that over 40 percent of VZV meningitis patients had residual symptoms at the time of assessment, compared with about 13 percent of patients with other types of viral meningitis.¹² That gap is striking. It suggests VZV meningitis tends to be a more aggressive illness than meningitis caused by, say, enteroviruses. Residual symptoms can include persistent headache, fatigue, cognitive complaints, and in some cases ongoing nerve pain similar to postherpetic neuralgia.

The patients who had the worst residual symptoms tended to be those who started antiviral treatment late and those who had worse baseline health going into the illness. Age also played a role, which fits with the broader pattern of older adults being more vulnerable to VZV complications.

The Stroke Connection

Beyond meningitis, VZV reactivation carries another neurological risk that gets less public attention: stroke. The virus can infect blood vessel walls in the brain, a condition called VZV vasculopathy, leading to inflammation, narrowing, and blood clots. Studies show a roughly 1.5-fold increase in stroke risk in the first month after a shingles episode, and that elevated risk can persist for years afterward.¹⁴ The risk is particularly high when shingles affects the ophthalmic branch of the trigeminal nerve, producing the painful eye condition known as herpes zoster ophthalmicus.

The vascular complications of VZV can cause ischemic strokes (from blocked blood flow), hemorrhagic strokes (from bleeding), and even aneurysms or clots in the venous sinuses of the brain.¹⁴ These complications can develop independently of meningitis or alongside it. The broader point is that VZV, once reactivated, has a particular affinity for the nervous system and its blood supply. Meningitis is one expression of that affinity, and stroke is another.

When Multiple Nerves Are Involved

VZV doesn’t always limit itself to one nerve. Ramsay Hunt syndrome, which occurs when the virus reactivates in the nerve responsible for facial movement and part of the ear, can happen at the same time as meningitis. Published cases document VZV meningitis occurring alongside or even preceding Ramsay Hunt syndrome in young, immunocompetent adults, confirming that central nervous system infection and peripheral nerve damage can co-exist.⁷ In one unusual case, VZV reactivation simultaneously affected the mandibular branch of the trigeminal nerve, the facial nerve, and the meninges, all in a patient with a normal immune system.¹⁵

These multi-nerve cases tend to be more severe and more likely to leave lasting deficits like facial weakness or hearing loss. They also illustrate how VZV reactivation can spread through interconnected nerve pathways once it gains a foothold, especially when the virus reaches the spinal fluid and has access to nerves bathed in it.

Prevention Through Vaccination

The most effective way to reduce the risk of VZV meningitis is to prevent shingles from occurring in the first place. The recombinant zoster vaccine (sold as Shingrix) provides roughly 95 percent protection against shingles in immunocompetent adults aged 50 and older, based on randomized trial data. Observational studies confirm substantial real-world protection as well, and follow-up data suggest the vaccine’s effects last at least 11 years.¹⁶ Because the vaccine dramatically reduces the chance of VZV reactivation, it should in turn reduce the risk of all the neurological complications that flow from reactivation, including meningitis, vasculopathy, and Ramsay Hunt syndrome.

No vaccine trial has been large enough or specifically designed to measure its effect on VZV meningitis as a standalone outcome, since VZV meningitis is uncommon enough that you’d need enormous numbers to detect a statistically meaningful difference. But the logic is straightforward: if the virus doesn’t reactivate, it can’t reach the central nervous system. For adults over 50, and increasingly for younger immunocompromised patients who qualify, vaccination is the single most important preventive step.

Why VZV Meningitis Gets Overlooked

Several factors conspire to make VZV meningitis fly under the radar. First, it isn’t a reportable disease in most countries, so surveillance data are thin. Second, many mild cases may resolve without a lumbar puncture ever being performed, especially in younger patients who present with headache and a stiff neck but improve quickly. Third, the zoster sine herpete phenomenon means that even when a spinal tap is done, doctors may not think to order VZV-specific PCR testing if there is no rash pointing them toward the virus. And fourth, the assumption persists among both patients and some clinicians that shingles is a skin disease, full stop. The neurological dimensions of VZV reactivation remain underappreciated relative to the rash and the postherpetic pain that dominate public awareness.

That blind spot has real consequences. As the data on treatment delay show, recognizing VZV meningitis early and starting antivirals promptly can meaningfully change the odds of a full recovery. Anyone with shingles who develops severe headache, confusion, neck stiffness, or unusual neurological symptoms like dizziness or weakness should seek urgent medical evaluation. And anyone with those symptoms and no rash should be aware that shingles-related meningitis remains a possibility worth investigating.

1
PubMed Central. Varicella Zoster Virus in the Nervous System
2
Canadian Journal of General Internal Medicine. An Unusual Presentation of Varicella Meningitis: A Case Report and Review of the Literature
3
PubMed Central. Meningitis without Rash after Reactivation of Varicella Vaccine Strain in a 12-Year-Old Immunocompetent Boy
4
PubMed. Clinical features of viral meningitis in adults: significant differences in cerebrospinal fluid findings among herpes simplex virus, varicella zoster virus, and enterovirus infections
5
PubMed Central. Stroke-like Symptoms as Presenting Signs of Varicella Zoster Meningitis in an Immunocompetent Adult
6
BMJ Case Reports. Varicella-zoster virus meningitis with hypoglycorrhachia, presenting with painless occipital herpes zoster mimicking atopic dermatitis
7
PubMed Central. Two cases of Ramsay-Hunt syndrome following varicella zoster viral meningitis in young immunocompetent men: case reports
8
PubMed Central. Varicella-Zoster as a Cause of Aseptic Meningitis in an Immunocompetent Young Patient With Skin Rash
9
PubMed Central. Acyclovir-induced neurotoxicity with a positive cerebrospinal fluid varicella zoster PCR result creating a management dilemma: a case report
10
Clinical Chemistry. A-278 Use of Antibody Index Calculation to Detect Intrathecal VZV IgG Antibody Synthesis to Aid in the Diagnosis of VZV Infections of the CNS
11
PubMed Central. Varicella Zoster aseptic meningitis: Report of an atypical case in an immunocompetent patient treated with oral valacyclovir
12
PubMed Central. Prognostic Factors and Clinical Characteristics of Varicella Zoster Virus Meningitis: Impact of Treatment Delay and Age-Related Differences in a Japanese Tertiary Hospital
13
ScienceDirect / Journal of the Neurological Sciences. Nationwide epidemiology, treatment patterns, and clinical outcomes of varicella-zoster virus meningitis in Japan
14
PubMed Central. Stroke from Infection
15
PubMed Central. Herpes Zoster Infection Involving Mandibular Division of Trigeminal Nerve and Ramsay Hunt Syndrome with Meningitis in an Immunocompetent Patient: A Rare Association
16
PubMed Central. Efficacy and Effectiveness of the Recombinant Zoster Vaccine Against Herpes Zoster, Herpes Zoster Ophthalmicus, Postherpetic Neuralgia and Dementia: A Systematic Review and Meta‐Analysis